These results indicate that the presence of an antigen-expressing B16-OVA tumor may lead not only to an antigen priming effect and increased antigen-specific CD8+ T cells upon VSV-GP-OVA vaccination, but also may redirect the subtype composition towards the SLEC phenotype in the tumor as well as the peripheral blood. Here, CD8A is linked to neoplasm.